Health regulator authorizes Indian company to sell first generic Ozempic in Canada
Health Canada has authorized Dr. Reddy’s Laboratories Ltd., an Indian pharmaceutical company, to sell the first generic version of Ozempic in Canada. The approval, granted on Tuesday, allows the company to market an injectable form of semaglutide, the drug's active ingredient. Although generic semaglutide became legally permissible in Canada on January 5, no applications had been approved until now. Dr. Reddy’s has already been selling the generic drug in India.
Opening excerpt (first ~120 words) tap to expand
Open this photo in gallery:A doctor in Mumbai displays the Ozempic GLP-1 self-injectable at a clinic.INDRANIL MUKHERJEE/AFP/Getty ImagesShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountIndian pharmaceutical company Dr. Reddy’s Laboratories Ltd. has become the first drug maker authorized to sell a generic version of the blockbuster drug Ozempic, according to Health Canada.The regulator’s website was updated Tuesday afternoon to show that it issued a notice of compliance to Dr. Reddy’s that day to make an injectable form of semaglutide, the active ingredient in Ozempic and Wegovy.Generic semaglutide became legal in Canada as of Jan. 5, but Health Canada did not approve any of the active applications from six drug makers until now.Dr.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Globe and Mail.
Discussion
0 commentsMore from The Globe and Mail
